The translocator protein TSPO is in an important diagnostic and therapeutic target in a range of pathologies, including neuroinflammation and cancer. Despite the availability of several structures of TSPO homologues, our understanding of the molecular determinants that govern high-affinity interactions of TSPO with its ligands is incomplete. Here, in order to decipher the key structural elements of TSPO responsible for interactions with its ligands, we designed a panel of chimeric proteins mimicking the mammalian substrate binding site grafted onto the backbone of the Rhodobacter sphaeroides TSPO homologue, RsTSPO. One of the designed chimeric constructs, RsMouse, could be heterologously expressed and displayed improved binding affinities for the known TSPO drugs diazepam, PK11195 and NBD-FGIN-1-27. Furthermore, the chimeric protein had improved interactions with NBD-cholesterol, a fluorescent analogue of the presumed natural substrate of TSPO. Partial modifications of the transmembrane helix bundle in the chimeric construct differentially affected binding of the TSPO drugs and the natural substrates of TSPO, consistent with the presence of multiple ligand binding sites in the protein. Based on the available structures of TSPO homologues, the substrate interactions may involve a lateral opening of the protein in the TM1-3, and stabilisation of TM4-5 is important for drug-like ligand binding. These observations are consistent with our experimental results, which show that the determinants of high-affinity ligand interactions of TSPO are distinct for different classes of ligands.
Introduction
The translocator protein, TSPO, was first described in 1977 as a secondary target of diazepam (hence one of its original names, Peripheral Benzodiazepine Receptor, PBR) [1, 2] . It is an 18 kDa protein with five α-helical transmembrane helices (TM1-5), located in the outer mitochondrial membrane [3] . In mammals, TSPO is expressed ubiquitously [4] , with high expression levels in steroidogenic tissues [5] . The amino acid sequence of TSPO is highly conserved across species, from bacteria to higher eukaryotes [6] .
The molecular structure of TSPO has been extensively characterised. Our first structure of the R. sphaeroides TSPO (RsTSPO) at a resolution of 10 Å confirmed that the monomeric TSPO forms dimers in the membrane, with each monomer composed of 5 TM helices. Each TM bundle forms a putative substrate/ligand binding site open laterally to the lipid bilayer [7] . This arrangement of TM helices was recently confirmed by high-resolution X-ray structures of RsTSPO [8] and of a homologue from Bacillus cereus [9] . Moreover, a structure of the monomeric mouse TSPO has been solved by NMR [10] . TSPO has attracted great interest as a pharmacological target due to multiple studies linking it with a variety of pathologies. Its expression is downregulated in several psychiatric disorders such as anxiety disorders and schizophrenia [11, 12] . Furthermore, TSPO is up-regulated in peripheral nervous system lesions [12] , brain damage [13] , neuroinflammation [14, 15] , aggressive breast cancer [16, 17] and in several neurodegenerative diseases such as Parkinson's [18, 19] and Alzheimer's [20, 21] .
The molecular function of mammalian TSPO has been a subject of intense debates [22] [23] [24] [25] . According to one of the active hypotheses, TSPO may participate in a large mitochondrial membrane complex that includes the voltage-dependent anion channel (VDAC), adenine nucleotide translocase (ANT) and steroidogenic acute regulatory protein (StAR) [26] . This complex facilitates the translocation of cholesterol across the outer to the inner mitochondrial membrane at the membrane contact sites. Following the translocation, cholesterol enters the first step of neuroactive steroid synthesis, i.e. it is converted to the endogenous steroid pregnenolone by the cytochrome P450 side chain cleavage enzyme (P450ssc) [27] . According to this model, TSPO regulates the rate-limiting phase of steroidogenesis: translocation of cholesterol across the outer mitochondrial membrane [2] .
In bacteria, the functional role of TSPO homologues has largely been studied using the species of Rhodobacter as model organisms. The RsTSPO was shown to regulate photosynthetic gene expression [6, 28] and to act as an oxygen sensor [29] . Furthermore, TSPO has been suggested as a player in efflux of porphyrin biosynthetic intermediates [28] . Recent investigations involving Chlorobium tepidum TSPO suggested a possible role in cell detoxification via binding and chemical modification of porphyrins [30] . Thus, there is some degree of potential overlap in mammalian and bacterial TSPO homologues putative substrate/ligand specificity: porphyrins are intrinsic to prokaryotes as well as eukaryotes and have been suggested as substrates for bacterial and mammalian proteins alike.
The interest in TSPO as a potential drug target fuelled development of a wide range of drug-like small molecules that bind this protein with high affinity. The ligands that have been extensively used to characterise TSPO pharmacologically include the benzodiazepine diazepam and its analogue Ro5-4864 [31] , isoquinoline carboxamide PK11195 [32] and FGIN-1-27 [33] . These TSPO-binding drugs, as well as a range of other classes of chemicals, have been viewed as starting points for the development of novel ligands with improved properties that may be used to target TSPO in various clinical scenarios, e.g. for PET/SPECT imaging of glioma [34, 35] or for targeted cancer therapy [36] . Thus, although the long-standing models of molecular function of TSPO have been challenged by recent data in TSPO knock-out mice [37, 38] , the potential of TSPO ligands in a range of medical applications is widely acknowledged [12, 15, 39, 40] .
Bacterial expression of membrane proteins offers distinctive advantages over mammalian expression, combining low costs and high protein yields. In successful recombinant expression experiments, functional membrane proteins can be generated in quantities sufficient for structural characterisation. However, the caveat is in our current inability to efficiently produce mammalian membrane proteins in E. coli, due to: (i) possible requirements of specialised protein production and quality control machinery which E. coli cells may lack, and (ii) differences in composition of the lipid bilayer that may be sub-optimal for insuring correct membrane protein folding. In the case of mammalian TSPO, expression in E.coli has been performed for many years, but it was typically followed by treatment with harsh solubilising reagents for membrane extraction and isolation of the protein [41, 42] . This hints at fundamental incompatibility of E. coli as a host for recombinant expression of functionally intact mammalian TSPO. Despite our recent progress in establishing methods for purification of mammalian TSPO expressed in HEK293 cells [43] , structural and functional characterisation of the purified mammalian TSPO homologues remains a challenge.
We endeavoured to circumvent this problem by utilising the wellcharacterised RsTSPO as an expression and folding "backbone". We reasoned that studying the determinants of ligand binding should be possible in the context of a mammalian-like ligand binding site engineered into a bacterial protein, provided that the folding of the protein is not drastically perturbed. Similar approaches have been Overview of the experimental strategy. Three R. sphaeroides/mammalian chimeric constructs were generated by substituting the putative binding site residues in the bacterial TSPO with the equivalent residues in the mammalian TSPO homologues. The expression levels and ability to bind to known TSPO ligands were assessed. Using constructs that displayed the highest expression levels as the starting point, partial chimeric constructs were generated to further characterise the regions of the protein important in ligand binding. B. Sequence alignment of wild-type R. sphaeroides and mammalian TSPO as well as the three generated bacterial/mammalian chimeric constructs. TM1 to TM5 are indicated in colour below the sequence alignment. The sequence alignment was generated in Jalview using ClustalX colour code.
previously used in the study of neurotransmitter transporters [44] and ABC transporters [45] . Based on the published TSPO structures, a ligand binding site would likely involve residues either pointing into the cavity formed by the TM helices, or residues in close proximity to this region, with preference for residues exposed to the cytosolic side of the membrane.
A striking property of the TSPO family proteins in bacteria and eukaryotes is their ability to bind similar chemicals with relatively high affinity [29, 46] . Bacterial TSPO homologues could in principle be used as a model for binding of natural and synthetic ligands by mammalian TSPO. However, as the binding sites are not expected to be highly conserved, our experimental strategy involved designing and validating a model chimeric construct of RsTSPO mutated to incorporate putative binding site residues from a mammalian homologue. The results of the experiments performed using this and derivative constructs allowed us to reconcile the structural evidence available from the X-ray and NMR structures, and to identify parts of the protein essential for high-affinity interactions with the TSPO-targeting drugs.
Materials and methods

Reagents
All chemicals used in buffer preparations were from Gerbu except imidazole which was from Merck and EDTA from Sigma. LB medium for small-scale bacterial cultures was from Conda. TB medium for protein expression was prepared using reagents from Gerbu. Detergents (dodecylmaltoside, sol-grade and ana-grade) were purchased from Anatrace. HisPur Cobalt resin was from Thermo Fischer Scientific.
TSPO ligands
The ligands were purchased from Roche (Diazepam; Cat. no. Cat. no. ALX-620-045).
Molecular cloning
All DNA constructs for bacterial expression were generated by cloning the custom-synthesised DNA fragments (Genewiz) into pET28a Chromatograms are normalised to 10 g of cell pellet to compare expression levels. Fractions pooled for functional studies are marked with dashed lines. B. Binding of the drugs PK11195 and diazepam to the three Rs/mammalian TSPO chimeras and the bacterial wild-type. Purified TSPO was mixed with the increasing concentrations of ligand, the tryptophan fluorescence was measured at 340 nm and plotted against the ligand concentration. All assays were repeated three times. From the obtained binding curves, it can be seen that affinity of both ligands is clearly increased for RsMouse compared to the bacterial wildtype (EC50 values shown in Table S1 ).
plasmid between XbaI and XhoI restriction sites, using standard ligation protocol (QuickLigase, New England Biolabs); all constructs contain a C-terminal 10xHis tag.
Protein expression
Plasmids were transformed into BL21(RIPL) cells and grown in TBglucose medium at 37°C. Expression was induced with 0.4 mM IPTG and performed at 32°C for 3 h. Cells were harvested by centrifugation and flash frozen until the day of experiment.
Cobalt affinity chromatography
Cell pellets were resuspended in buffer A (50 mM Tris pH 7.5, 200 mM NaCl, 2 mM β−mercaptoethanol) using a homogeniser, 0.5 mM PMSF and 5 μg/mL DNAse was added and the cell wall broken by applying the sample to a continuous flow cell disruptor EmulsiFlex-C3 (Avestin) for four cycles. Membranes were spun down by ultracentrifugation (Beckman Coulter Optima XL 100k Ultracentrifuge, 35000 rpm, Ti45, 4°C), resuspended in buffer B (50 mM Tris pH 7.5, 200 NaCl, 10% glycerol, 2 mM β−mercaptoethanol) with 20 mM imidazole and 1% DDM (sol-grade; in all subsequent steps ana-grade detergent was used) was added for solubilisation. After 1 h of incubation at 4°C with stirring, the insoluble material was removed by centrifugation (HiCen 21,19,000 rpm, A8.24, 4°C). The supernatant was added to HisPur Cobalt resin in batch and incubated with rotation at 4°C for 1 h. The mixture was collected into a gravity column (BioRad), allowing the lysate to flow through. The resin was washed with 10 column volumes of buffer C (50 mM Tris pH 7.5, 200 mM NaCl, 10% glycerol, 2 mM β−mercaptoethanol, 0.02% DDM) with 25 mM imidazole, followed by 20 column volumes of buffer C with 50 mM imidazole. The protein was eluted using 4 column volumes of buffer C containing 250 mM imidazole. The eluted fractions were concentrated using an Amicon concentrator (50,000 MWCO) at 2500 xg. The final purification step, size-exclusion chromatography, was performed using the ÄKTApure system (GE Healthcare Life Sciences). The concentrated protein was injected onto a Superdex-200 Increase column pre-equilibrated with 20 mM Tris pH 7.5, 200 mM NaCl, 0.5 mM EDTA and 0.02% DDM. The fractions containing TSPO were pooled and concentrations determined with a NanoDrop.
Intrinsic tryptophan fluorescence-based binding assays
All assays were performed in black Greiner 96 well plates using the PHERAstar FSX plate reader at 28°C (Optical module FL ex280 em340). The sample volume was 120 μl/well, the final protein concentration was 1 μM and ligands were added in a range of concentrations. The highest ligand concentration in the assay depended on the solubility of the ligand and was 200 μM for diazepam and PK11195, 40 μM for protoporphyrin IX, 20 μM for NBD-FGIN-1-27, and 75 μM for NBDcholesterol. Ligand stocks were made with DMSO and working stocks with assay buffer (50 mM Tris pH 7.5, 200 mM NaCl, 0.5 mM EDTA and 0.02% DDM). Samples were incubated at RT for 10 min before the measurement.
For curve-fitting, emission values recorded at 340 nm were used as a function of ligand concentration after subtraction of the background. EC50 and Kd values were calculated using non-linear regression in GraphPad Prism 7.0. For the EC50 values, the dose response model ([agonist] vs. response) was used for all 5 ligands. To obtain the Kd values for cholesterol, the receptor binding model assuming two sites and specific binding was used. All experiments were performed three times for diazepam, PK11195, NBD-F-GIN-1-27 and protoporphyrin IX. The experiments using NBD-cholesterol were performed five times. Statistical significance of the observed differences in the EC50 and Kd values was estimated using one-way Anova (GraphPad Prism).
Results
Design and validation of the RsMouse TSPO chimera
Analysis of the published RsTSPO structures [8] revealed 38 residues that could potentially constitute a part of the ligand or substrate binding pocket (Fig. 1) . These residues were mutated to produce three R. sphaeroides/mammalian (RsHuman, RsMouse and RsBovine) chimeric constructs. All three "chimeras" could be expressed in E.coli and purified by affinity and size-exclusion chromatography ( Fig. 2A ). While the RsHuman and RsBovine mutants yielded substantially less protein than the bacterial wild-type construct, the RsMouse chimera could be produced in a quantity similar to that of the wild-type RsTSPO.
In order to determine whether the chimeric proteins were purified in a functional form, we tested their ability to bind the known TSPO ligands. An established and robust binding assay, based on intrinsic tryptophan fluorescence quenching, was used for all constructs and The residues that were mutated back to the parental construct in the seven partial chimeric constructs are shown in colour. The sketch was generated using Protter [48] . B. Structure of the R. sphaeroides wild-type TSPO (pdb id 4UC1). Residues mutated to the mammalian ones in the partial RsMouse H chimeric constructs are shown in colour. The structure was modelled using PyMol. ligands in this study, similar to the previous studies of TSPO ligand binding [7, 47] . The binding assays revealed that the RsMouse chimera has a significantly improved binding affinity for diazepam ( Fig. 2B , Table S1 ). Thus, our approach to mutating the residues lining the putative ligand binding site surface of the bacterial TSPO, substituting it with the corresponding residues of the mouse homologue, yielded a well expressed and folded TSPO construct with higher affinities for known TSPO drugs.
RsMouse H shows improved affinity for TSPO ligands and drugs
For the RsMouse chimera we generated two alternative constructs: RsMouse and a mutant that contained a histidine instead of an arginine in position 46 (RsMouse-R46H, or RsMouse H ). At this position, the human TSPO homologue has a histidine residue, whereas this residue in the RsTSPO, the bovine and the mouse TSPO is an arginine (Fig. 3A) . Biochemical characterisation of RsMouse and the R46H mutant revealed a 1.6-fold improvement of expression levels of the protein, judged by the amount of purified protein per weight of cell pellet of two small-scale expression/purification experiments (Fig. 3B) . Moreover, the mutant showed higher affinity for protoporphyrin IX (Table 1, Fig.  S1 ). Thus, the RsMouse H was chosen as the parental construct in the subsequent experiments aimed at identifying the regions of the protein contributing towards the improved binding affinity of the TSPO ligands and substrates.
Partial chimeric constructs help identify ligand binding determinants
To further assess which of the mutated residues in TSPO chimeras contribute to observed higher affinities we mutated portions of the RsMouse H back to RsTSPO (Fig. 4) . The produced constructs (TM1-TM5, Loop and C-terminus) were subjected to the same procedures as were used for the complete chimeric protein construct. Of those seven partial chimeric constructs, all but one (Loop) could be successfully expressed and purified (Fig. 5, Fig. S2 , Table S2 ). The SEC profiles were normalised to the weight of cell pellets used for protein purification to account for the difference in the expression levels. The broader peak for RsMouse H is most likely due to overloading the detector as the yield for this construct was especially high. Although the behaviour of the partial chimeric constructs in SEC experiments suggested presence of mixed populations of oligomeric states, the isolated SEC fractions were monodisperse and could be used for the functional studies ( Fig. 5) . It is possible that in some of the cases the broadening of the SEC peaks, changes in peak elution volumes and the appearance of additional peaks closer to or wat the void volume reflect changes in protein oligomerization. For example, it is possible that the TM4 mutant has substantial changes in its propensity to oligomerize via the membraneembedded or solvent-exposed portions of the protein, leading to higher apparent molecular weight in SEC (Fig. 5, Fig. S2 ). Defining the nature of the physical changes in the proteins that are associated with the changes in the SEC profiles will require careful future experimentation.
Intrinsic tryptophan fluorescence-based binding assays were performed with three artificial TSPO ligands (PK11195, diazepam and NBD-FGIN-1-27) and the two natural TSPO ligands (protoporphyrin IX and NBD-cholesterol). Due to poor solubility, NBD-derivatives of FGIN-1-27 and cholesterol were used instead of FGIN-1-27 and cholesterol, respectively.
Analysis of the binding data for diazepam and PK11195 revealed TM4 and TM5 as the two regions of the protein that may be important for establishing a high-affinity binding site in chimeric TSPO. The variation of affinities for NBD-FGIN-1-27 was much less pronounced and there appeared to be no significant difference in this ligand's interaction with RsMouse H and with RsTSPO. The tolerance of NBD-FGIN-1-27 to the changes in the protein hints at slightly different requirements for recognition of this ligand by TSPO that we have not perturbed by our mutations. Nevertheless, the 2-fold reduction in the EC50 for NBD-FGIN-1-27 in TM4 construct, compared to the full chimeric protein, is consistent with the observations with PK11195 and diazepam ( Fig. 6 , Table 2 ).
High-affinity interactions with substrates are mediated by nonoverlapping parts of TSPO
The two putative natural ligands of TSPO, protoporphyrin IX and cholesterol (its NBD-derivative), showed distinctly different profiles of interaction with the RsMouse constructs. The affinity of protoporphyrin IX was similar for RsTSPO and for RsMouse H . We observed the strongest effect on protoporphyrin IX binding in the TM5 construct, with a 3-fold reduction in affinity compared to the control proteins ( Fig. 7, Table 2 ).
In the case of NBD-cholesterol, the analysis of binding data for cholesterol was substantially limited by the apparent presence of multiple binding sites. In addition to the one-site model, we used the twosite model for curve-fitting as a tool for interpreting our results (Table  S3 ) It is important to stress that the mode in which cholesterol interacts with TSPO is likely more complex than would be predicted by a two-site model. Nevertheless, for the purpose of this study, our analysis showed that the two-site model could be used for all mutants except the TM2 and TM3. These two constructs, in addition to TM1, also showed the strongest changes in the "high-affinity" binding site for NBD-cholesterol Fig. 7 . Tryptophan quenching assays results for TSPO ligands. Ligand binding was measured by addition of the increasing amounts of ligand to the purified protein at 1 μM, measuring the tryptophan fluorescence at 340 nm and plotting the signal against the ligand concentration. Each assay was performed three times for protoporphyrin IX and five times for NBD-cholesterol. On the left, binding curves for the controls RsMouse H and wild-type RsTPO in comparison. On the right, binding curves for all six partial RsMouse H chimeric constructs with the back-mutations introduced as shown in Fig. 4 . The curves for RsMouse H and RsTSPO are shown as dashed lines for comparison.
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Protein Expression and Purification 164 (2019) 105456 ( Fig. 6 , Table S3 ). The different effects of the mutations in TM1-3 on binding of NBD-cholesterol, compared to the binding of drug-like molecules, suggests that the binding sites and binding site determinants for cholesterol and artificial ligands of TSPO may be non-overlapping. Interestingly, changes in TM5 or the C-terminus of the chimeric protein had little or no effect on NBD-cholesterol binding, despite the reported importance of these parts of the protein for cholesterol binding [49] .
Discussion
We have successfully generated a chimeric model TSPO protein that combines the ease of expression of a bacterial protein with the highaffinity ligand binding properties of the mammalian TSPO. Previous mutational studies in RsTSPO, including structure-function studies of single site mutations and the structural characterisation of RsTSPO, showed that the protein can be effectively used as a model for the mammalian proteins [30, 46] . The high value of such an approach was illustrated by a recently published structure of RsTSPO at high resolution that helped explain the molecular effects of a disease-related single nucleotide polymorphism of TSPO [8] . The chimeric construct described here extends the observations made previously using individual mutants.
Our strategy was contingent on the tolerance of the TSPO fold for changes in residues potentially involved in ligand binding. The possibility of simultaneously mutating nearly 20% of the protein while yielding a functionally expressed protein construct points to a remarkable conservation of the TSPO fold from prokaryotes to mammals. Recent studies raised questions about the exact physiological function of TSPO [37, 38, 50] . The preservation of the core elements of TSPO structure from simple organisms to mammals, and the seemingly interchangeable ligand binding pocket-exposed parts of the protein, point to a high likelihood of a shared basic function of the distantly related homologues of TSPO.
Whereas the full chimeric construct with all mutations introduced simultaneously could be expressed with high yield, the loop mutant could not be successfully produced (Fig. 5 ). The loop region in the mammalian TSPO is three residues longer than the corresponding loop in RsTSPO. The failed expression of the loop mutant could mean that the three residue difference is tolerated by the protein only when additional mutations are present elsewhere in the protein. It is possible that the mutated loop region is in close proximity to a secondary mutated site (in another loop, TM domain or in the C-terminus), allowing the protein to adopt a stable fold.
Our study provides important insights into the interactions between TSPO proteins and their ligands. It has been previously reported that the binding sites for PK11195, protoporphyrin IX and cholesterol in RsTSPO are not identical [47, 51] . Our results indicate that a unique set of binding site residues is utilised by TSPO to engage each ligand with high affinity. Moreover, in the case of the three synthetic ligands (PK11195, diazepam and FGIN-1-27), mutations in TM4 appear to be of greatest consequence for binding to the protein (Figs. 6 and 7; Table 2 ). The substitutions in TM4 are conservative, with a notable presence of a bulky residue in place of a polar one (S116W). Two out of three mutated residues are predicted to point directly into the putative ligand binding site, based on the X-ray structure of RsTSPO (pdb ID 4UC1 [8] ) and BcTSPO (pdb ID 4RYI [9]) (Fig. S3 ). The residue of RsTSPO corresponding to the S116W mutant is located at the interface between TM4 and TM5 (Fig. S3 ). It is possible that the observed effects or apparent drug binding affinities are due to changes in stability of the protein in the presence of the mutations in the TM4-TM5 region. The observation of functional consequences of the mutations in this region may prove useful in the future efforts to develop ligands with higher affinity for mammalian TSPO.
Unlike in the case of the drug-like molecules, binding of a TSPO substrate analogue NBD-cholesterol is most sensitive to mutations in TM1 and TM3. Previous studies suggested that cholesterol may bind to TSPO at the protein-lipid interface [52] . This could be reconciled with our results, considering modest effects on NBD-cholesterol binding of the core ligand binding site mutations that clearly affected the drug binding. Interestingly, binding of NBD-cholesterol to TSPO in our assays clearly deviated from a single site binding mode (Fig. 7) . Instead, the binding experiments reveal behaviour more consistent with a mixture of high-affinity and low-affinity binding sites. It is likely that a number of factors can influence this behaviour, including a choice of the detergent, consistent with [47] , and the hydrophobicity of the ligand. Our results strongly suggest that the "core" binding site of the protein formed by TM1-3 (similar to the porphyrin site in RsTSPO structure) plays a role in sterol recognition; it is possible that there is a complex interplay between this site and sites at the protein-lipid interface of TSPO.
A Cholesterol Recognition Amino acid Consensus (CRAC) motif has been proposed to play an important role in cholesterol binding by TSPO. Similar motifs, corresponding to a consensus sequence L/ V−(X) 1-5 −Y−(X) 1-5 −R/K, have been found in a variety of sterolbinding proteins across species [49] . Although in some cases the bioinformatics predictions were validated by structural evidence, there have also been instances where the predicted CRAC motifs could not be confirmed as true cholesterol binding regions [53] . In TSPO, a CRAC sequence residues in the C-terminal part of TM5, close to the solventexposed C-terminal region (Fig. S3 ). Contrary to our expectations, substitution of the "canonical" CRAC residues in the chimeric construct with the corresponding residues from RsTSPO did little to the apparent affinity for NBD-cholesterol ( Fig. 7) . Instead, TM1 and TM3 appeared to have the strongest contribution toward binding of the sterol. It is possible that in the detergent environment the C-terminal region of the protein that contains the CRAC motif contributes less to the sterol-TSPO interaction than the core elements of the protein, i.e. residues in TM1 and TM3 (Fig. S3) .
The recently published structure of RsTSPO featured a porphyrin molecule bound in a pocket between TM1 and TM3 [8] . Interestingly, our data indicate that TM5 plays a role in porphyrin binding. The likely explanation for this is that the mutations in TM5 destabilise the porphyrin binding pocket, exerting a similar effect on porphyrin binding as on the interactions with the drug-like ligands. The relatively mild effect of the mutations in TM1-3 on porphyrin interactions with TSPO points at a highly conserved mode of interaction between the protoporphyrin IX and the protein.
The future direction of research utilising the chimeric TSPO proteins may involve their in-depth biochemical and structural characterisation. The approach described here has obvious limitations: the readout is based on studying the effects of the mutations on protein-drug interactions, and detailed insights into the structure of TSPO would require more direct approaches (i.e., traditional structural studies). Furthermore, any effects of the mutations on protein stability and oligomeric state may influence the observed results and may complicate a straight-forward interpretation of the experimental data. Thus, the future efforts in structural characterisation of the native and chimeric TSPO proteins will require careful investigation of their biophysical and structural properties. Our study did not address the translocation of the substrates by TSPO, focusing exclusively on the binding of the substrates and drugs to the purified protein. It is likely that the mutations that affect substrate recognition also influence the ability of the protein to transport its substrates across the membrane. Studies of the sterol or porphyrin transport by the wild-type and chimeric TSPO proteins may provide valuable insights into the substrate translocation process. Furthermore, the beneficial properties of the RsMouse chimeric constructs (including their high yield and mammalian TSPO-like ligand binding characteristics) may facilitate structural characterisation of TSPO by X-ray crystallography, NMR or cryo-EM.
In conclusion, the structure-function relationship study of the chimeric TSPO proteins has provided new insights into the molecular determinants of ligand recognition by TSPO. Our results complement and reconcile the available structural data on bacterial and mammalian TSPO homologues, and provide further evidence for the evolutionary conservation of the essential parts of the protein involved in ligand and substrate recognition.
